Eli Lilly (LLY)

AutoZone, Eli Lilly, Meta Platforms, and Costco all trade at high share prices, making them candidates for stock splits as analysts raise price targets and cite strong fundamentals.

The Vanguard Morningstar Mega Cap Growth ETF offers concentrated exposure across the artificial intelligence (AI) value chain.

Consumer spending on healthcare is relatively more stable compared to most other industries.

The company has a history of developing treatments that have achieved widespread adoption.

This stock is worth loading up on whenever it's on the cheap side.

Bristol Myers Squibb trades at a fraction of Eli Lilly's valuation while generating substantial free cash flow, but concentration risk and explosive growth tell very different stories.

Both stocks may be worth considering for those looking to capitalize on the anti-obesity market.

Consistency is one of the biggest factors in making it happen.

Higher inflation rates have caused investors to rethink their portfolios.

Shares of Viking Therapeutics took off recently after the company released some promising data about its GLP-1 drug.

Something new is happening in the weight loss drug market.

The company recently delivered some exciting trial data, but it also needs to deliver in the second part of the trial.

Eli Lilly's share price climb has decelerated in 2026.

Eli Lilly is the leader in the GLP-1 space, but not every new drug the company is working on will be a winner.

The "Magnificent Seven" ETF finally topped the record high it set in May.

A weekly roundup of MarketBeat analysis on volatile markets, oil, bond rates, AI stocks, dividend picks, and earnings outlooks, covering companies from NVIDIA to Tesla and Qualcomm.

The drugmaker badly needs more clinical wins.

The biotech player could eventually rival big pharma companies.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...

AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after The U.S. Food and Drug Administration ...

XLV offers exposure to the broader healthcare sector, while IBB targets biotech innovators. Here's how the two stack up on risk, returns, and diversification.

VanEck's concentrated 25-stock biotech portfolio surged 40.5% in one year, but Fidelity's diversified 365-holding fund delivered superior risk-adjusted returns with half the volatility.